ZNF239

ZNF239/MOK2 is a Krüppel-family zinc finger protein that functions as a sequence-specific transcriptional repressor and nuclear matrix-associated factor (PMID:2104662, PMID:9121460). Its DNA-binding activity resides in seven adjacent zinc finger motifs that recognize a defined 18-bp element, and the same protein binds RNA homopolymers while associating with nucleolar and extranucleolar ribonucleoprotein structures (PMID:9121460). At target promoters such as IRBP, MOK2 represses transcription by competing with the activator CRX for an overlapping core binding sequence (PMID:11278819). The human ortholog carries an N-terminal acidic domain that mediates a direct physical interaction with nuclear lamin A/C through the lamin coiled-2 domain, tethering a fraction of MOK2 to the nuclear matrix (PMID:12409453). This interaction is regulated by phosphorylation within the lamin A/C-binding domain — at Ser38/Ser129 by JNK3 and at Ser46 by Aurora A and PKA — which interferes with lamin A/C binding, and MOK2 additionally associates with the JLP and JSAP1 scaffold proteins (PMID:19490114). Pathogenic lamin A/C missense mutations do not abolish the interaction itself but sequester MOK2 into aberrant nuclear aggregates, providing a route to deregulation of its target genes (PMID:17760566).

1. 1990 Medium

   Established the gene product as a Krüppel-family zinc finger protein composed almost entirely of zinc finger domains, implicating it in transcription before any target was known.

   Evidence cDNA/genomic cloning, sequencing and Northern blot expression profiling in mouse

   PMID:2104662

   Open questions at the time

   • No DNA target or transcriptional activity demonstrated
   • Functional role inferred only from domain structure
2. 1994 Medium

   Characterized the MOK-2 promoter architecture, showing it is TATA/CCAAT-less and subject to negative cis-regulation by repetitive B2 elements, addressing how the gene's own expression is controlled.

   Evidence Promoter deletion/reporter assays and DNA sequence analysis

   PMID:7959005

   Open questions at the time

   • Trans-acting factors controlling the promoter not identified
   • Physiological contexts of regulation unknown
3. 1995 Medium

   Defined structural divergence between human and mouse orthologs, revealing that human MOK2 carries extra N-terminal zinc fingers and a 173-aa acidic domain absent in mouse, while the seven core fingers are conserved.

   Evidence cDNA/genomic cloning, sequencing, Southern blot and FISH mapping to 19q13.2-q13.3

   PMID:8587123

   Open questions at the time

   • Function of the human-specific acidic domain not yet defined
   • Functional consequence of extra zinc fingers unknown
4. 1997 High

   Identified the dual nucleic-acid binding capacity and defined the specific 18-bp DNA recognition sequence, localizing DNA binding to the seven zinc fingers and linking the protein to nuclear RNP structures.

   Evidence SELEX, RNA homopolymer binding assays, and immunofluorescence/immunoelectron microscopy across human and mouse orthologs

   PMID:9121460

   Open questions at the time

   • No endogenous genomic targets identified
   • Functional role of RNA binding unresolved
5. 2001 High

   Demonstrated a concrete repressor mechanism by showing MOK2 binds a core element in the IRBP promoter overlapping the CRX site and represses transcription through competition with the CRX activator.

   Evidence DNA-binding assays, transient transfection reporter assays and CRX competition binding in Weri-RB1 retinoblastoma cells

   PMID:11278819

   Open questions at the time

   • Repression shown by overexpression, not endogenous loss-of-function
   • Broader target gene set not defined
6. 2002 High

   Connected MOK2 to nuclear architecture by mapping a direct lamin A/C interaction to its N-terminal acidic domain and the lamin coiled-2 domain, with a fraction in the nuclear matrix.

   Evidence Yeast two-hybrid, GST pull-down, co-immunolocalization and nuclear matrix fractionation

   PMID:12409453

   Open questions at the time

   • Functional consequence of tethering for transcription not established
   • Dynamics of matrix association unknown
7. 2008 Medium

   Linked MOK2 to laminopathy mechanisms by showing pathogenic lamin A/C mutations sequester MOK2 into nuclear aggregates despite preserving the binding interaction, suggesting target-gene deregulation.

   Evidence In vitro binding assays and co-immunolocalization in cells expressing lamin A/C mutants

   PMID:17760566

   Open questions at the time

   • Target-gene deregulation only inferred, not directly measured
   • Disease relevance to specific laminopathy phenotypes not demonstrated
8. 2009 High

   Revealed phosphoregulation of the lamin interaction, identifying JNK3, Aurora A and PKA sites in the lamin A/C-binding domain whose phosphorylation disrupts lamin binding, plus scaffold partners JLP and JSAP1.

   Evidence In vitro kinase assays, site-directed mutagenesis, phospho-dependent binding assays and co-IP for partner identification

   PMID:19490114

   Open questions at the time

   • Signaling stimuli that trigger these phosphorylations in vivo unknown
   • Transcriptional output of release from lamin not measured

• The genome-wide target repertoire and the physiological/developmental processes governed by ZNF239 repression remain undefined.
• No ChIP-seq or knockout phenotype available
• RNA-binding function lacks a defined biological role
• In vivo significance of nuclear aggregation untested